BioSpace News Archive

The global stem cells market is predicted to witness players seeking funds from international organizations for developing new therapies.

The company is planning for its drug for cholesterol lowering medications to hit the streets by the end of March. It will provide a new option to all the patients.

Via a five-year collaborative research pact, Harvard and Guangzhou Institute will split $115 million in research funding provided by China Evergrande Group.

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40th Annual Health Care Conference at 4:50 p.m. ET on Monday, March 2, 2020, at the Boston Marriott Copley Place, Boston.

Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, today announced the initiation of a Phase 2 trial of SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist in clinical development as a non-hormonal once-daily (QD) treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes.

The venture capital fund AmorChem II is very proud to announce the financing of a new university project focusing on preclinical development of retinal gene augmentation to treat Peroxisome Biogenesis Disorders in the Zellweger spectrum (PBD-ZSD).

ReadCoor, Inc., a company leading true multi-omic spatial sequencing, today unveils its first product line, including multi-omic spatial sequencing assays and the RC2 instrument.

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide‐Releasing Anti- Inflammatory Drug (ATB‐352): A Role for Endogenous Cannabinoids”.

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, reported financial results for the fourth quarter and full year ended December 31, 2019.

PPG announced initiatives to support coronavirus relief efforts in China.